Funding for this research was provided by:
National Institute on Drug Abuse (R25DAO33211)
Received: 21 April 2021
Accepted: 9 July 2021
First Online: 12 April 2022
: Dr. Weiss has served as a consultant to Astellas Pharmaceuticals, Cerevel Therapeutics, Analgesic Solutions, Takeda Pharmaceuticals, and Janssen Pharmaceuticals. Dr. Kleinman has received funding from the Centre for Addiction and Mental Health Discovery Fund and the Research in Addiction Medicine Scholars Program (National Institute on Drug Abuse R25DAO33211) and travel awards from the American Psychiatric Association and the American Academy on Addiction Psychiatry.